The company's manufacturing capacity has reached 26 billion units per year, a fourfold increase over several years. Marksans aims for ₹4,000 crore revenue in 2-3 years with projected 20% growth in the US market. The company has recently formed wholly owned subsidiaries in Ireland and Canada to expand its pharmaceutical business internationally.
Cyborg Score Rationale
Q3 FY26 revenue grew 10.6% YoY to ₹754.4 crore with EBITDA of ₹160.7 crore. 9M FY26 EBITDA margin of 19.4% aligns with full-year guidance of 19-20%. Recent regulatory approvals and international expansion position the company well for sustainable growth.
Top Insights
Q3 net profit rose to ₹1.13B from ₹1.05B YoY, demonstrating profitability growth.
Stock surged 9.5% on February 3, 2026, reflecting positive market sentiment.
Time-Cap Laboratories (US subsidiary) received clean Establishment Inspection Report from FDA in October 2023 with no 483s issued.
Relonchem (UK subsidiary) received MHRA approval for Cyanocobalamin 50mg tablets, expanding UK market access.
Named Competitors
Generic Pharmaceuticals — Leading large-cap Indian pharma manufacturer
Generic Pharmaceuticals — Major competitor with diverse therapeutic portfolio
Generic Pharmaceuticals — API and formulation manufacturer
Generic Pharmaceuticals — Global pharmaceutical company
Recent Developments
(February 2026) Formed wholly owned subsidiaries Marksans Pharma Europe Limited and Marksans Canada Inc.
(February 2026) Q3 FY26 results showed 10.6% YoY revenue growth with EBITDA margin aligned to guidance
(January 2026) Announced ₹4,000 crore revenue target for 2-3 years with 20% US market growth projection
(November 2025) UK unit received MHRA approval for Cetirizine Oral Solution
Open the full interactive Marksans Pharma Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.